Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cell signaling

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    67 result(s) found for: Cell signaling. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2012-000601-74 Sponsor Protocol Number: PCI-32765MCL3001 Start Date*: 2014-01-24
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Controlled, Open-Label, Multicenter Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Versus Temsirolimus in Subjects with Relapsed or Refractory Mantle Cell L...
    Medical condition: Relapsed or refractory Mantle Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026801 Mantle cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed) DE (Completed) GB (Completed) IE (Completed) HU (Completed) PT (Completed) CZ (Completed) NL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-006224-21 Sponsor Protocol Number: IJB-BCTL-20119167 Start Date*: 2013-06-20
    Sponsor Name:Jules Bordet Institute
    Full Title: A pre-operative window study evaluating Denosumab, a RANK-Ligand (RANKL) inhibitor and its biological effects in young pre-menopausal women diagnosed with early breast cancer
    Medical condition: We have designed this study to investigate if denosumab can modulate a number of biological processes including prolferation, RANK signaling and the mammary stem cell subpopulation.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004945-27 Sponsor Protocol Number: SHH4476g Start Date*: 2009-07-09
    Sponsor Name:Genentech, Inc.
    Full Title: A PIVOTAL PHASE II, MULTICENTER, SINGLE ARM, TWO-COHORT TRIAL EVALUATING THE EFFICACY AND SAFETY OF GDC-0449 IN PATIENTS WITH ADVANCED BASAL CELL CARCINOMA
    Medical condition: • metastatic BCC with histologic confirmation of a distant BCC metastasis (e.g., lung, liver, lymph nodes, or bone) • locally advanced BCC considered inoperable or with medical contraindication to...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004146 Basal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-019348-37 Sponsor Protocol Number: CLDE225X2104 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase 1 study of LDE225 in pediatric patients with recurrent or refractory medulloblastoma or other tumors potentially dependent on the Hedgehog-signaling pathway
    Medical condition: pediatric patients with recurrent or refractory medulloblastoma or other tumors potentially dependent on the Hedgehog-signaling pathway (rhabdomyosarcoma, neuroblastoma, hepatoblastoma, high-grade ...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066594 Medulloblastoma recurrent LLT
    12.1 10039027 Rhabdomyosarcoma recurrent LLT
    12.1 10066595 Neuroblastoma recurrent LLT
    12.1 10065443 Malignant glioma LLT
    12.1 10031296 Osteosarcoma recurrent LLT
    12.1 10019823 Hepatoblastoma recurrent LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-003755-41 Sponsor Protocol Number: ERIS Start Date*: 2021-10-12
    Sponsor Name:Region Skåne
    Full Title: ERIS- EGFR-Mutated Lung Cancer in Randomized Investigator-Initiated Study
    Medical condition: EGFR-mutated non-small cell lung cancer (NSCLC) not amenable for curative treatment intention and candidates for EGFR-inhibitor in first line.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000102-19 Sponsor Protocol Number: HL_VL_01_2015 Start Date*: 2015-07-07
    Sponsor Name:Section for Surgical Pathophysiology, Rigshospitalet
    Full Title: Effect of preoperative intravenous highdose methylprednisolone on orthostatic intolerance, sleeping pattern, glucose homeostasis and immune signaling in patients scheduled for total hip-arthroplasty
    Medical condition: Hip joint arthrosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004859 10003416 Arthrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-000199-41 Sponsor Protocol Number: GESIDA10918 Start Date*: 2019-07-10
    Sponsor Name:Fundación SEIMC-GESIDA
    Full Title: A phase IV, multicenter, open and randomized study to evaluate the impact of the change of antiretroviral treatment from dual therapy to triple therapy on inflammation in patients with type 1 HIV i...
    Medical condition: HIV
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10001509 AIDS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000711-88 Sponsor Protocol Number: PCI-32765MCL2001 Start Date*: 2012-09-13
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2, Multicenter, Single-Arm, Study to Evaluate the Efficacy and Safety of Single-Agent Bruton' s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects with Mantle Cell Lymphoma Who Progres...
    Medical condition: Mantle Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) GB (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004937-26 Sponsor Protocol Number: GELLC-7 Start Date*: 2017-07-13
    Sponsor Name:Fundación PETHEMA
    Full Title: A multicenter, non-randomized, open label study to evaluate the efficacy and security of Ibrutinib followed by ofatumumab consolidation in previously untreated patients with Chronic Lymphocytic Leu...
    Medical condition: Chronic Lymphocytic Leukemia or Lymphocytic Small Cell Lymphoma without previous treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10051812 Small cell lymphocytic lymphoma LLT
    20.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001640-56 Sponsor Protocol Number: PI12/01866 Start Date*: 2014-01-31
    Sponsor Name:Fundación Para la Investigación Biomédica de Córdoba
    Full Title: Crossover clinical trial, randomized, double blind, placebo controlled trial. Modulation of cellular mediators and repair endothelial damage in patients with chronic renal disease through inhibitio...
    Medical condition: Patients with chronic kidney disease and asymptomatic hyperuricemia on the balance of mechanisms of vascular injury and repair.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002753-11 Sponsor Protocol Number: TofaSTAT17 Start Date*: 2018-01-25
    Sponsor Name:Tampere University Hospital
    Full Title: The effect of tofacitinib on the activity of JAK-STAT pathways in patients with rheumatoid arthritis (RA)
    Medical condition: Rheumatoid arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2015-004274-15 Sponsor Protocol Number: Pelle-926-201 Start Date*: 2016-02-22
    Sponsor Name:PellePharm, Inc.
    Full Title: Double-Blind, Randomized, Vehicle-Controlled Proof of Concept Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndr...
    Medical condition: Basal Cell Nevus Syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004850 10004151 Basal cell nevus syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-004140-32 Sponsor Protocol Number: PRP-MUSCULO-2014-01 Start Date*: 2014-04-28
    Sponsor Name:Unidad de Cirugia Artroscópica
    Full Title: CLINICAL STUDY TO ASSES THERAPEUTIC USE OF PLATELET RICH PLASMA IN ACUTE MUSCLE INJURIES IN ELITE ATHLETES"
    Medical condition: Acute Muscle Injury Type 3A-3B (Munich classification) or type II (Classification of Otto Chan), confirmed by radiological diagnosis and clinical agreement.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10028395 - Musculoskeletal and connective tissue disorders 10028391 Musculoskeletal pain PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002468-41 Sponsor Protocol Number: Dial-1 Start Date*: 2018-06-21
    Sponsor Name:University Medical Center of the Johannes Gutenberg- University Mainz
    Full Title: A phase I/II multicenter, open-label Study of DKN-01 to investigate the anti-tumor activity and safety of DKN-01 in Patients with Hepatocellular Carcinoma and WNT signaling Alterations
    Medical condition: Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003398-79 Sponsor Protocol Number: MH21HEM Start Date*: 2023-05-11
    Sponsor Name:Princess Máxima Center for pediatric oncology
    Full Title: International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies in children Subprotocol D: Trametinib + Dexamethasone + C...
    Medical condition: Molecularly profiled r/r ALL/LBL whose tumor harbors an actionable event that can be targeted by the investigational agents. In this subprotocol, patients must present alterations in the RAS signal...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-007768-41 Sponsor Protocol Number: CA196-005 Start Date*: 2009-10-16
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer wi...
    Medical condition: Recurrent or Advanced Non-Small Cell Lung Cancer with Non-Squamous Histology
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000201-72 Sponsor Protocol Number: 1 Start Date*: 2012-05-11
    Sponsor Name:University of Aberdeen [...]
    1. University of Aberdeen
    2. University of Aberdeen
    Full Title: The Effects of Inorganic Nitrite on cardiac and skeletal muscle: Physiology, Pharmacology and Therapeutic Potential. Peripheral Arterial Disease
    Medical condition: Peripheral arterial Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-019817-20 Sponsor Protocol Number: Start Date*: 2010-11-15
    Sponsor Name:Institut Bergonié
    Full Title: A phase II study of GDC-0449 in patients with advanced chondrosarcomas.
    Medical condition: Adult patients with unresectable locally advanced or metastatic chondrosarcomas.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10008736 Chondrosarcoma metastatic LLT
    Population Age: Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004113-13 Sponsor Protocol Number: CLDE225XBE01T Start Date*: 2012-11-05
    Sponsor Name:GZA vzw, GZA Ziekenhuizen, Sint-Augustinus
    Full Title: A Phase II, Open-Label, Safety, Efficacy and Pharmacodynamic Study of oral sonidegib in patients with Basal Cell Carcinoma (BCC) and prior exposure to Hedgehog Pathway inhibitors
    Medical condition: Basal Cell Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-007155-27 Sponsor Protocol Number: ARQ197-215 Start Date*: 2009-10-22
    Sponsor Name:ArQule, Inc.
    Full Title: A Randomized Controlled Phase 2 Trial of ARQ 197 in Patients with Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy
    Medical condition: Unresectable hepatocellular carcinoma (HCC)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 08:20:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA